New Albany Biologics Manufacturing Expansion (2025 Phase)

$900M expansion of Amgen's New Albany, Ohio biologics manufacturing site announced April 25, 2025. Adds 350 additional full-time jobs on top of the 400 at the initial facility, bringing Amgen's Central Ohio totals to more than $1.4B and about 750 jobs. Separately tracked from the 2021 initial facility to distinguish the two capital commitments; the initial facility's $365M / 400 jobs and the more-than-$1.4B site rollup are explicitly excluded from these figures.

Investment
$900.0M
Permanent jobs announced
350
Status
Under Construction
Expected opening
Jan 1, 2027
Why this project qualifies

With $900 million in facility-specific investment and 350 permanent operating jobs announced, this project clears both of AFT's qualifying thresholds ($100 million in facility-specific investment OR 100 permanent operating jobs). This project also meets AFT's primary-source verification and physical U.S. manufacturing-footprint requirements.

View full methodology →
Why it matters

The pharmaceuticals context.

Pharmaceutical manufacturers are committing billions to new U.S. production capacity for active ingredients, injectable medicines, biologics and other high-demand treatments. North Carolina and Indiana remain major centers of investment, while new facilities are being planned across the South. The current project pipeline includes both large greenfield campuses and major expansions of established production sites.

Project record

At a glance

Company
Amgen (New Albany Expansion)
Industry
Pharmaceuticals
Location
New Albany, Ohio
Investment
$900.0M
Permanent jobs announced
350
Status
Under Construction
Announced
Apr 25, 2025
Expected opening
Jan 1, 2027
Added to tracker
Feb 25, 2026
Sources

Official references

Related

Other projects to know

Back to the tracker/projects/amgen-new-albany-expansion-new-albany